Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure

BACKGROUND. Mitoxantrone was approved for use in metastatic castrate-resistant prostate cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase III trial in 1996. To re-evaluate for possible survival benefits in a larger contemporary sample and to demonstrate analy...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncologist
Prif Awduron: Green, Angela K., Corty, Robert W., Wood, William A., Meeneghan, Mathew, Reeder-Hayes, Katherine E., Basch, Ethan, Milowsky, Matthew I., Dusetzina, Stacie B.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AlphaMed Press 2015
Pynciau:
Genitourinary Cancer
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4425389/
https://ncbi.nlm.nih.gov/pubmed/25888270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0432
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg